Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02483910 · ClinicalTrials.gov registry record · NA
Direct Instruction Language for Learning in Autism Spectrum Disorder
A NA study, sponsored by Emory University.
- Completed
- Registry status
- NA
- Development phase
- 137
- Enrollment target
NCT02483910: Completed NA study, sponsored by Emory University.
NCT02483910 is a NA study that has completed, run by Emory University. The registered enrollment target is 137 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02483910, a NA study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- NA
- Development phase
- 137 participants
- Enrollment target
Study Summary
The purpose of this study is to test whether Direct Instruction - Language for Learning (DI-LL) is an effective way to teach language skills to children with autism spectrum disorder (ASD) and moderate language delay. Direct Instruction - Language for Learning (DI-LL) uses face to face instruction and specific lessons to teach children language skills. This method has been used previously in children with language delays, but it has not been carefully studied in children with autism spectrum disorder. This study will compare DI-LL and ongoing treatment as usual to treatment as usual (speech therapy, language services, etc.) alone.
Primary Outcome
The CELF-4 English Version will be administered to assess the participant's (aged 5-8 years) receptive and expressive language skills.The Core Language score quantifies a participant's overall language performance. The standard score for the Core Language scale is based on a mean of 100 with a standard deviation of 15 (average range of 85-115). The higher the score, the better the language function of the participant.
Interventions
- BEHAVIORAL Direct Instruction-Language for Learning (DI-LL) via telehealth (e.g., Zoom or WebEx)
- BEHAVIORAL Standard of care delivered via telehealth (e.g., Zoom or WebEx)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2015-10 |
| Est. Completion | 2020-11-24 |
| Phase | NA |
What the finished NCT02483910 record still lists
NCT02483910 is an interventional study that assigns participants to a tested intervention. The registered 137 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 2 interventions - of which Direct Instruction-Language for Learning (DI-LL) via telehealth (e.g., Zoom or WebEx) is the first listed.
NCT02483910 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02483910 about?
NCT02483910 is a clinical study titled "Direct Instruction Language for Learning in Autism Spectrum Disorder". The purpose of this study is to test whether Direct Instruction - Language for Learning (DI-LL) is an effective way to teach language skills to children with autism spectrum disorder (ASD) and moderate language delay. Direct Instruction - Language for Learning (DI-LL) uses face to face instruction a...
What is the current status of trial NCT02483910?
This trial is currently completed. It is a NA study. The enrollment target is 137 participants. The study started on 2015-10. Estimated completion is 2020-11-24.
What interventions are being tested in trial NCT02483910?
The interventions under investigation include: Direct Instruction-Language for Learning (DI-LL) via telehealth (e.g., Zoom or WebEx) (BEHAVIORAL), Standard of care delivered via telehealth (e.g., Zoom or WebEx) (BEHAVIORAL).
Who is sponsoring clinical trial NCT02483910?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02483910's enrollment target sits among peer trials
137 722nd of 2000 higher than 1,279 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05091424 · 137 participants · Phase 1
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- NCT05655182 · 137 participants · Phase 1
A Study of BLB-201 RSV Vaccine in Infants and Children
- NCT06571669 · 137 participants · NA
BOOM-IBD2 Pivotal Clinical Trial
- NCT06644768 · 137 participants · Phase 1
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia